Orfadin PIL
... There are no adequate and well-controlled studies with ORFADIN in pregnant women. However, animal reproduction studies have been conducted for nitisinone. In these studies, nitisinone was administered to mice and rabbits during organogenesis with oral doses of nitisinone up to 20 and 8 times respect ...
... There are no adequate and well-controlled studies with ORFADIN in pregnant women. However, animal reproduction studies have been conducted for nitisinone. In these studies, nitisinone was administered to mice and rabbits during organogenesis with oral doses of nitisinone up to 20 and 8 times respect ...
Antibiotics - DENTISTRY 2012
... Broad spectrum β-Lactam antibiotics Highly resistant to most β-lactamases. Imipenem has a wide spectrum against many gramnegative rods, including Pseudomonas aeruginosa, gram-positive organisms, and anaerobes. Carbapenems are one of the antibiotics of last resort for many bacterial infections, such ...
... Broad spectrum β-Lactam antibiotics Highly resistant to most β-lactamases. Imipenem has a wide spectrum against many gramnegative rods, including Pseudomonas aeruginosa, gram-positive organisms, and anaerobes. Carbapenems are one of the antibiotics of last resort for many bacterial infections, such ...
valproates - DavisPlus
... Monitor hepatic function (LDH, AST, ALT, and bilirubin) and serum ammonia concentrations prior to and periodically during therapy. May cause hepatotoxicity; monitor closely, especially during initial 6 mo of therapy; fatalities have occurred. Therapy should be discontinued if hyperammonemia occurs. ...
... Monitor hepatic function (LDH, AST, ALT, and bilirubin) and serum ammonia concentrations prior to and periodically during therapy. May cause hepatotoxicity; monitor closely, especially during initial 6 mo of therapy; fatalities have occurred. Therapy should be discontinued if hyperammonemia occurs. ...
Boxed Warnings Adverse Drug Reactions Poster
... spontaneous, surgical, and medical abortions, including following Mifeprex* use. No causal relationship between the use of Mifeprex and misoprostol and these events has been established. Before prescribing Mifeprex, inform the patient about the risk of these serious events and discuss the MEDICATION ...
... spontaneous, surgical, and medical abortions, including following Mifeprex* use. No causal relationship between the use of Mifeprex and misoprostol and these events has been established. Before prescribing Mifeprex, inform the patient about the risk of these serious events and discuss the MEDICATION ...
OPIOIDS
... lorcet, percodan, percocet, vicodin, oxycontin) – with chronic pain or terminal patients – in some cough suppressants ...
... lorcet, percodan, percocet, vicodin, oxycontin) – with chronic pain or terminal patients – in some cough suppressants ...
15-2-7to10抗真菌病毒抗结核2
... immitis（粗球孢子菌）; Pathogenic molds（致病霉菌）, such as Aspergillus fumigatus （ 曲霉）and mucor（毛霉 ...
... immitis（粗球孢子菌）; Pathogenic molds（致病霉菌）, such as Aspergillus fumigatus （ 曲霉）and mucor（毛霉 ...
Highlights of Products Added via Special Authorization (SA
... ECDET agrees that there is a significant concern regarding non-judicious use of broad-spectrum fluoroquinolones. As a result, it was recommended that these agents not be added since no therapeutic or cost advantage was seen in listing these products. ...
... ECDET agrees that there is a significant concern regarding non-judicious use of broad-spectrum fluoroquinolones. As a result, it was recommended that these agents not be added since no therapeutic or cost advantage was seen in listing these products. ...
Superficial fungal infections
... elevation has been described, and several cases of drugassociated hepatic necrosis have been reported. Alopecia has been reported as a common adverse event in patients receiving prolonged high-dose therapy. Coadministration of enzyme inhibitor fluconazole with phenytoin results in increased serum phe ...
... elevation has been described, and several cases of drugassociated hepatic necrosis have been reported. Alopecia has been reported as a common adverse event in patients receiving prolonged high-dose therapy. Coadministration of enzyme inhibitor fluconazole with phenytoin results in increased serum phe ...
Plaquenil (hydroxychloroquine sulfate)
... arrhythmias if PLAQUENIL is used concomitantly with other arrhythmogenic drugs. An increased plasma ciclosporin level was reported when ciclosporin and PLAQUENIL were co-administered. PLAQUENIL may also be subject to several of the known interactions of chloroquine even though specific reports have ...
... arrhythmias if PLAQUENIL is used concomitantly with other arrhythmogenic drugs. An increased plasma ciclosporin level was reported when ciclosporin and PLAQUENIL were co-administered. PLAQUENIL may also be subject to several of the known interactions of chloroquine even though specific reports have ...
Prior Authorization Guideline
... 2. Nausea and Vomiting The use of dronabinol for chemotherapy induced nausea and vomiting was evaluated in a randomized controlled trial comparing the combination of dronabinol and prochlorperazine with either agent along (n=62).6 The use of combination therapy was associated with significantly shor ...
... 2. Nausea and Vomiting The use of dronabinol for chemotherapy induced nausea and vomiting was evaluated in a randomized controlled trial comparing the combination of dronabinol and prochlorperazine with either agent along (n=62).6 The use of combination therapy was associated with significantly shor ...
Document
... Eleven characteristic mutations Having one or even two doesn’t confer clinical resistance Mostly different from other PI mutations C. Loveday study: DRV mutations in 14% of patients failing PIs: only 1.5% with ≥ 3: only 2 patients (out of 885) with 5 Did not occur before 2000 so other PIs can genera ...
... Eleven characteristic mutations Having one or even two doesn’t confer clinical resistance Mostly different from other PI mutations C. Loveday study: DRV mutations in 14% of patients failing PIs: only 1.5% with ≥ 3: only 2 patients (out of 885) with 5 Did not occur before 2000 so other PIs can genera ...
Indocollyre leaflet
... - lithium (described with other NSAIDs): lithium blood levels may increase to toxic levels; this effect is due to decreased lithium excretion by the kidney. If necessary, monitor lithium blood levels closely and adjust the lithium dosage during combined treatment then after the NSAID is withdrawn. - ...
... - lithium (described with other NSAIDs): lithium blood levels may increase to toxic levels; this effect is due to decreased lithium excretion by the kidney. If necessary, monitor lithium blood levels closely and adjust the lithium dosage during combined treatment then after the NSAID is withdrawn. - ...
SUSCEPTIBILITY PROFILE OF STREPTOCOCCUS PYOGENES
... and clindamycin is the preferred antibiotic in the treatment of patients with serious soft tissue infections, due to its ability to inhibit the production of several streptococcal virulence factors. Currently, resistance to erythromycin and related antibiotics represents a significant cause for conc ...
... and clindamycin is the preferred antibiotic in the treatment of patients with serious soft tissue infections, due to its ability to inhibit the production of several streptococcal virulence factors. Currently, resistance to erythromycin and related antibiotics represents a significant cause for conc ...
Anti-amebiasis Drugs
... A nitroimidazole. The nitro group of metronidazole is chemically reduced in anaerobic bacteria and sensitive ...
... A nitroimidazole. The nitro group of metronidazole is chemically reduced in anaerobic bacteria and sensitive ...
Tizanidine - NHS Trafford CCG
... Notify the consultant of willingness accept shared care. Prescribe therapy recommended by the consultant with minimum delay. Treatment may be initiated in clinic, but more often the consultant will advise treatment with Tizanidine. Notes on treatment When treating a patient with normal renal functio ...
... Notify the consultant of willingness accept shared care. Prescribe therapy recommended by the consultant with minimum delay. Treatment may be initiated in clinic, but more often the consultant will advise treatment with Tizanidine. Notes on treatment When treating a patient with normal renal functio ...
Summary of the risk management plan
... Overview of disease epidemiology Ikervis is a medicine used to treat severe keratitis (inflammation of the cornea, the transparent layer at the front of the eye), in patients with dry eye disease for whom treatment with artificial tears (tear substitutes) is insufficient. In dry eye disease not enou ...
... Overview of disease epidemiology Ikervis is a medicine used to treat severe keratitis (inflammation of the cornea, the transparent layer at the front of the eye), in patients with dry eye disease for whom treatment with artificial tears (tear substitutes) is insufficient. In dry eye disease not enou ...
Treatment of Hayfever Vol 3 No 2 (PDF 46Kb)
... Terfenadine was the first to be marketed. Others include astemizole, loratadine and cetirizine. They are less likely to cross the blood-brain barrier minimizing their sedative effect and cholinergic action. Astemizole has a slow onset of action and a long half-life so dosing should ideally be starte ...
... Terfenadine was the first to be marketed. Others include astemizole, loratadine and cetirizine. They are less likely to cross the blood-brain barrier minimizing their sedative effect and cholinergic action. Astemizole has a slow onset of action and a long half-life so dosing should ideally be starte ...
Hypertensive patients with concomitant diseases
... ACE inhibitors are most effective in hypertensive patients who are white and young . ACE inhibitors slow the progression of diabetic nephropathy and decrease albuminuria. ACE inhibitors are also effective in the management of patients with chronic heart failure. ACE inhibitors are a standard in the ...
... ACE inhibitors are most effective in hypertensive patients who are white and young . ACE inhibitors slow the progression of diabetic nephropathy and decrease albuminuria. ACE inhibitors are also effective in the management of patients with chronic heart failure. ACE inhibitors are a standard in the ...
Product information - XATRAL® SR
... this episode, to postpone the risk of need for surgery. In the first phase of this double-blind placebo controlled study, alfuzosin (sustained release formulation) 10mg/day (N=241) or placebo (N=122) was administered for a duration of 3 to 4 days following urethral catheterisation for AUR (starting ...
... this episode, to postpone the risk of need for surgery. In the first phase of this double-blind placebo controlled study, alfuzosin (sustained release formulation) 10mg/day (N=241) or placebo (N=122) was administered for a duration of 3 to 4 days following urethral catheterisation for AUR (starting ...
NOURIAST Tablets 20 mg
... In repeated-dose toxicity studies in mice, rats, and dogs and carcinogenicity studies in mice and rats, inflammatory changes in the lung characterized by inflammatory macrophages (development, aggregation, or increase of macrophages/foamy macrophages/histiocytes/foamy histiocytes in the alveolar spa ...
... In repeated-dose toxicity studies in mice, rats, and dogs and carcinogenicity studies in mice and rats, inflammatory changes in the lung characterized by inflammatory macrophages (development, aggregation, or increase of macrophages/foamy macrophages/histiocytes/foamy histiocytes in the alveolar spa ...
Xamic - Renata Limited
... the plasminogen tissue activator. This fact is particularly important for the clinical use of Xamic ®, because it ensures an antihemorrhagic activity with an antifibrinolytic mechanism under a variety of conditions. The acute toxicity of Xamic ® is extremely low and chronic toxicity almost non-exist ...
... the plasminogen tissue activator. This fact is particularly important for the clinical use of Xamic ®, because it ensures an antihemorrhagic activity with an antifibrinolytic mechanism under a variety of conditions. The acute toxicity of Xamic ® is extremely low and chronic toxicity almost non-exist ...
PACKAGE LEAFLET TINIDAZOL ATC code
... Tinidazol is rapidly absorbed from gastrointestinal tract after oral reception. Maximal plasma concentrations are reached about 2 hours after the reception and are maintained 12 hours. It is bound to plasma proteins in about 12 %. It is ...
... Tinidazol is rapidly absorbed from gastrointestinal tract after oral reception. Maximal plasma concentrations are reached about 2 hours after the reception and are maintained 12 hours. It is bound to plasma proteins in about 12 %. It is ...
anadrol®-50 - Meda Pharmaceuticals
... area) had increased incidences of lung alveolar/bronchiolar adenoma and adenoma or carcinoma combined. At 100 mg/kg/day (about 3 fold the maximum recommended clinical dose of 5 mg/kg/day based on BSA), female rats had increased incidences of hepatocellular adenoma and adenoma or carcinoma combined; ...
... area) had increased incidences of lung alveolar/bronchiolar adenoma and adenoma or carcinoma combined. At 100 mg/kg/day (about 3 fold the maximum recommended clinical dose of 5 mg/kg/day based on BSA), female rats had increased incidences of hepatocellular adenoma and adenoma or carcinoma combined; ...
Why isn’t hydrocodone listed in Formulary? the FORMULARY UPDATE
... daily while taking lomitapide. The safety and efficacy of lomitapide were evaluated in a clinical trial of 29 patients with HoFH. On average, levels of LDL-C fell by approximately one-half during the first 26 weeks among those who tolerated the drug. Lomitapide carries a boxed-warning regarding a ...
... daily while taking lomitapide. The safety and efficacy of lomitapide were evaluated in a clinical trial of 29 patients with HoFH. On average, levels of LDL-C fell by approximately one-half during the first 26 weeks among those who tolerated the drug. Lomitapide carries a boxed-warning regarding a ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.